日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis

转移性神经内分泌肿瘤患者接受肽受体放射性核素治疗联合钬-166-选择性内放射治疗(HEPAR PLuS)与单纯肽受体放射性核素治疗的疗效比较:一项倾向评分匹配分析

Veldhuis, W B; Walter, T; de Vries-Huizing, D M V; Theysohn, J; Barton, S; Ekkelenkamp, E D; Lachachi, B; de Jong, R J G; van Golen, L W; Lanzafame, H; Milot, L; Lahner, H; Lam, M E G H; Tesselaar, M E T; Braat, A J A T

Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA)

动脉内肽受体放射性核素治疗神经内分泌肿瘤肝转移:一项住院随机对照试验(LUTIA)

Ebbers, S C; Barentsz, M W; de Vries-Huizing, D M V; Versleijen, M W J; Klompenhouwer, E G; Tesselaar, M E T; Stokkel, M P M; Brabander, T; Hofland, J; Moelker, A; van Leeuwaarde, R S; Smits, M L J; Braat, A J A T; Lam, M G E H

Quantification of biochemical PSA dynamics after radioligand therapy with [(177)Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model

利用群体药代动力学/药效动力学模型对放射性配体治疗后[(177)Lu]Lu-PSMA-I&T治疗后的生化PSA动态变化进行定量分析

Siebinga, Hinke; de Wit-van der Veen, Berlinda J; de Vries-Huizing, Daphne M V; Vogel, Wouter V; Hendrikx, Jeroen J M A; Huitema, Alwin D R

Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)

对初治淋巴结阳性前列腺癌患者同时进行外照射放疗和[(177)Lu]Lu-PSMA-617治疗的耐受性研究,I期研究(PROQURE-I试验)

van der Sar, Esmée C A; Braat, Arthur J A T; van der Voort-van Zyp, Jochem R N; van der Veen, Betty S; van Leeuwen, Pim J; de Vries-Huizing, Daphne M V; Hendrikx, Jeroen M A; Lam, Marnix G E H; Vogel, Wouter V